# HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma

> **NCT02836548** · PHASE1,PHASE2 · COMPLETED · sponsor: **The Netherlands Cancer Institute** · enrollment: 33 (actual)

## Conditions studied

- Melanoma
- Skin Neoplasms

## Interventions

- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT02836548
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2023-11
- **Final completion:** 2023-11
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02836548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02836548, "HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02836548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*